Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)
Authors:
- Patrick Y. WenPWPatrick Y. Wen
- W.K. Alfred YungWYW.K. Alfred Yung
- Kathleen R. LambornKLKathleen R. Lamborn
- Andrew D. NordenANAndrew D. Norden
- Timothy F. CloughesyTCTimothy F. Cloughesy
- Lauren E. AbreyLALauren E. Abrey
- Howard A. FineHFHoward A. Fine
- Susan M. ChangSCSusan M. Chang
- H. Ian RobinsHRH. Ian Robins
- Karen FinkKFKaren Fink
- Lisa M. DeAngelisLDLisa M. DeAngelis
- Minesh MehtaMMMinesh Mehta
Open Access
- 1 December 2009
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 11 (6) , 853-860
Abstract
Platelet-derived growth factor (PDGF) and its receptors (PDGFR) are frequently coexpressed in meningiomas, potentially contributing to their pathogenKeywords
This publication has 46 references indexed in Scilit:
- Targeting PDGF Signaling in Carcinoma-Associated Fibroblasts Controls Cervical Cancer in Mouse ModelPLOS Medicine, 2008
- Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report1Neuro-Oncology, 2007
- Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08Clinical Cancer Research, 2006
- Population pharmacokinetics of imatinib and the role of α1‐acid glycoproteinBritish Journal of Clinical Pharmacology, 2006
- Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2005
- Clinical Pharmacokinetics of ImatinibClinical Pharmacokinetics, 2005
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- The Treatment of Recurrent Unresectable and Malignant Meningiomas with Interferon Alpha-2BNeurosurgery, 1997
- Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loopInternational Journal of Cancer, 1995
- A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group studyJournal of Neuro-Oncology, 1993